Anita T. Shaffer

Should genomic profiles be used routinely to determine which breast cancer patients receive adjuvant chemotherapy?

As immunotherapy options grow, oncologists will need new frameworks of reference for evaluating whether patients are benefiting from the treatments

Aflibercept, an investigational angiogenesis inhibitor, improved overall survival as a second-line treatment for patients with mCRC

Abiraterone acetate gains FDA approval by demonstrating the ability to extend survival in patients with metastatic castrate-resistant prostate cancer

The ambitious effort to portray the cancer journey of one fictional patient marks an intersection of medicine and entertainment that has attracted widespread attention

The chorus of support is growing among oncology experts for routine genetic testing of tumors from patients with advanced non-small cell lung cancer

Radiation therapy (RT) used in combination with hormonal approaches continues to be a viable strategy for treating localized high-risk prostate cancer patients

Hormonal therapies have long been the standard of care for metastatic advanced prostate cancer

As research into novel vaccine approaches for treating advanced prostate cancer continues...

A new prostate cancer screening test yielded more detailed and specific results for prostate-specific antigen

Iniparib remains an intriguing therapeutic possibility despite failing to meet its phase III primary endpoints

For the first time in at least 3 decades, the rate of women dying from lung cancer in the United States is declining

Bristol-Myers Squibb plans to start rolling out its newly approved melanoma drug ipilimumab (Yervoy) in the next several weeks

It has been more than half a century since radiation treatment was mistakenly deemed necessary to help infants with enlarged thymus glands avoid the risk of status lymphaticus and suffocation

The FDA has approved the novel drug ipilimumab for the treatment of patients with metastatic melanoma

Cancer researchers and patient advocates are hailing the FDA's approval of Yervoy (ipilimumab)

Breast cancer researcher Edith A. Perez, MD, is aiming to present more detailed study findings at national conferences later this year that will help clinicians better identify patients who would benefit from HER2 targeted treatment.

As the number of breast cancer survivors grows, so does the emphasis on establishing individualized survivorship plans

Preoperative neoadjuvant systemic therapy can be valuable for patients even if they do not achieve a pathologic complete response

Preoperative neoadjuvant systemic therapy can be valuable for patients even if they do not achieve a pathologic complete response

With thousands of clinical trials in play, many oncology specialists are reluctant to embrace findings from newly-released studies

Should genomic profiles be used routinely to determine which breast cancer patients receive adjuvant chemotherapy

Personalized treatment in oncology is a popular concept these days, but the goal remains elusive

It is time to rethink the way oncologists in the United States are treating ductal carcinoma in situ

The addition of sorafenib to capecitabine as a first-line therapy for patients with advanced breast cancer

The climate for medical malpractice litigation in breast cancer treatment seems to be worsening

Breast pain is among the most common reasons that women seek medical attention from a breast specialist.

Amid advances in gene-based cancer diagnostics, questions about the best use of molecular and cellular assays in practice are growing along with the new options for clinicians.

A drug that delivers paclitaxel in a novel way has yielded favorable results in a phase II trial of patients with advanced esophageal cancer, prompting the company developing the drug to plan a phase III trial.

Data from the phase III ZETA trial show that vandetanib (Zactima), a selective tyrosine kinase inhibitor, significantly slows the progression of advanced medullary thyroid carcinoma